Analysis

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Halozyme Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to HALO.

websiteHALO/analysis/HALO

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to HALO.

Stock profile

Ticker

HALO

Asset type

Stock

Market cap

$8.24B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Halozyme Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • HALO primary listing
  • RV7
  • A0DLHS
  • 0J2O
  • 1HALO

Latest Halozyme Therapeutics, Inc. news

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug...

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2026, and provi...

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncolog...

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under th...

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme H...

Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May 11, 2026, following...

Research sections

Valuation

Review valuation context for Halozyme Therapeutics, Inc..

Future growth

Review future growth context for Halozyme Therapeutics, Inc..

Past performance

Review past performance context for Halozyme Therapeutics, Inc..

Financial health

Review financial health context for Halozyme Therapeutics, Inc..

Dividend

Review dividend context for Halozyme Therapeutics, Inc..

Management

Review management context for Halozyme Therapeutics, Inc..

Ownership

Review ownership context for Halozyme Therapeutics, Inc..

Other information

Review other information context for Halozyme Therapeutics, Inc..

Community

Review community context for Halozyme Therapeutics, Inc..